Moderna Stock Price Today NASDAQ: MRNA Quote, Market Cap, Chart

You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time. While Moderna currently has a «Hold» rating among analysts, top-rated analysts believe these five stocks are better buys. MRNA formed a descending trendline comprised of a descending upper trendline resistance that started at $48.92, rfp template for app development converging with a flat-bottom lower trendline support at $33.31. The triangle encompasses the 17% gap down on the lowered guidance.

MRNA vs Biotech Stocks

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, personal finance education, top-rated podcasts, and non-profit The Motley Fool Foundation. Moderna lowered its 2025 sales guidance by roughly $1 billion, as it continues to cut costs. The biotech company now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of whi…

Beaten-Down Stocks That Haven’t Been This Cheap in More Than 3 Years: Are They Bargain Buys?

• Tuesday, Moderna Inc MRNA stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro.
• It could benefit from AI developments and is trading at a cheap price.
• A breakdown triggers if the stock falls below the lower trendline support.
• After submitting your request, you will receive an activation email to the requested email address.
• Moderna’s stock tumbles after a disappointing outlook for revenue and the need to accelerate its cost-cutting plan.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna (MRNA) shares will likely remain under scrutiny on Tuesday after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion. Shares of Moderna (MRNA) took off Tuesday when the biotech firm announced that the U.S. government has awarded it more than a half a billion dollars to develop a vaccine that can be used against bird … Moderna is testing a norovirus vaccine in a phase three trial, with results available as soon as this year.

For valuing companies that are loss-making or have lots of physical asset

A breakdown triggers if the stock falls below the lower trendline support. However, a breakout can trigger if the stock surges through the upper trendline resistance. Moderna expects to receive 10 product approvals in the next three years and is focused on its pipeline and cutting costs. However, the company has engaged in a cost-cutting plan that will lower research and development expenses to narrow its focus to getting its most promising drugs approved before the cash runs out.

US awards Moderna $590 million for bird flu vaccine development

Merck desperately needs Moderna’s mRNA-based Personal Cancer Vaccines («PCVs») to extend KEYTRUDA’s patent protection beyond 2028. Tuesday, Moderna Inc MRNA stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro. Eva Ados, ERshares COO consulting is more than giving advice and chief investment strategist, joins CNBC’s ‘Power Lunch’ to share outlooks on three stocks. CAMBRIDGE, Mass. & BRISBANE, Australia–(BUSINESS WIRE)–Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today annou…

Ellison mentioned using AI to help rapidly develop new vaccines as a benefit of Project Stargate, which is investing upwards of $500 billion in AI infrastructure in the United States over the next few years. Investors took this as a positive sign for Moderna stock, especially given that it could be an AI beneficiary. If you can use AI to make custom vaccines and cures for cancer, that could be a tremendous value to society and Moderna’s business. The maker of vaccines, including the mRNA vaccine for COVID-19, is amid a 90% stock price downturn. In fact, the share price is now only right around the same level as it was before the 2020 pandemic.

Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals

According to 20 analysts, the average rating for MRNA stock is «Hold.» The 12-month stock price forecast is $76.35, which is an increase of 84.38% from the latest price. On the positive side, however, it is not spreading between humans, and antiviral medicines already approved by the FDA have been effective against the illness. Moreover, most people only show minor symptoms after contracting it. MRNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by the U.S. government’s Department of Health and Human Services (HHS) on Friday. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.

• If you are a believer in mRNA technology, now may be a perfect time to load up on some Moderna stock.
• However, the company has engaged in a cost-cutting plan that will lower research and development expenses to narrow its focus to getting its most promising drugs approved before the cash runs out.
• MRNA formed a descending trendline comprised of a descending upper trendline resistance that started at $48.92, converging with a flat-bottom lower trendline support at $33.31.
• The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
• Shares of Moderna (MRNA) took off Tuesday when the biotech firm announced that the U.S. government has awarded it more than a half a billion dollars to develop a vaccine that can be used against bird …
• On January 13, 2025, Moderna provided a business update and also lowered full-year 2025 forecasts below estimates.

However, this week, the company got good news with a mention of mRNA vaccines at the Project Stargate announcement and a new contract with the European Union. Discover which analysts rank highest on predicting the price target of MRNA. Discover which analysts rank highest for MRNA overall weighted by direction, price target, and price movement. Earlier this month, Cal-Maine Foods (CALM), the biggest U.S. egg producer, said egg prices have continued to rise because of limits on production because of the bird flu outbreak. Shares of Moderna (MRNA) took off Tuesday when the biotech firm announced that the U.S. government has awarded it more than a half a billion dollars to develop a vaccine that can be used against bird flu. MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

US stocks saw a decline on Monday futures market symbols list as investors continued to unload key tech shares that have been driving the bull market. The S&P 500 fell by 0.2%, while the Nasdaq Composite dropped 0.8%. Select to analyze similar companies using key performance metrics; select up to 4 stocks.